Detailed information for compound 103493
Basic information
Technical information
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
No curated genes were found associated with this compound
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Trichomonas vaginalis | CMGC family protein kinase | 0.0556 | 0.6521 | 1 |
| Plasmodium falciparum | protein kinase 5 | 0.0556 | 0.6521 | 1 |
| Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0556 | 0.6521 | 0.6521 |
| Brugia malayi | hypothetical protein | 0.0394 | 0.4417 | 0.6774 |
| Echinococcus granulosus | cyclin dependent kinase | 0.0556 | 0.6521 | 0.6521 |
| Toxoplasma gondii | cell-cycle-associated protein kinase CDK, putative | 0.0556 | 0.6521 | 1 |
| Trichomonas vaginalis | CMGC family protein kinase | 0.0556 | 0.6521 | 1 |
| Echinococcus granulosus | cyclin dependent kinase 1 | 0.0556 | 0.6521 | 0.6521 |
| Schistosoma mansoni | serine/threonine protein kinase | 0.0556 | 0.6521 | 0.6521 |
| Leishmania major | cell division related protein kinase 2,cdc2-related kinase | 0.0556 | 0.6521 | 1 |
| Entamoeba histolytica | cell division protein kinase 2, putative | 0.0556 | 0.6521 | 1 |
| Brugia malayi | Protein kinase domain containing protein | 0.0556 | 0.6521 | 1 |
| Echinococcus multilocularis | cyclin dependent kinase 5 | 0.0556 | 0.6521 | 0.6521 |
| Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0556 | 0.6521 | 0.6521 |
| Trypanosoma brucei | cdc2-related kinase 1 | 0.0556 | 0.6521 | 1 |
| Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0556 | 0.6521 | 0.6521 |
| Echinococcus granulosus | 5'partial|cyclin dependent kinase 1 | 0.0556 | 0.6521 | 0.6521 |
| Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0556 | 0.6521 | 0.6521 |
| Trypanosoma cruzi | cdc2-related kinase 1 | 0.0556 | 0.6521 | 1 |
| Onchocerca volvulus | 0.0055 | 0 | 0.5 | |
| Echinococcus multilocularis | cyclin dependent kinase | 0.0556 | 0.6521 | 0.6521 |
| Giardia lamblia | Kinase, CMGC CDK | 0.0556 | 0.6521 | 1 |
| Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0556 | 0.6521 | 0.6521 |
| Entamoeba histolytica | cell division protein kinase 2, putative | 0.0556 | 0.6521 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0824 | 1 | 1 |
| Brugia malayi | cell division control protein 2 homolog | 0.0556 | 0.6521 | 1 |
| Schistosoma mansoni | cyclin-dependent kinase 5 activator | 0.0824 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0394 | 0.4417 | 0.4417 |
| Trypanosoma cruzi | cdc2-related kinase 3 | 0.0556 | 0.6521 | 1 |
| Trypanosoma cruzi | cdc2-related kinase 3 | 0.0556 | 0.6521 | 1 |
| Trypanosoma brucei | cdc2-related kinase 3 | 0.0556 | 0.6521 | 1 |
| Echinococcus multilocularis | cyclin dependent kinase 5 activator 1 | 0.0824 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0394 | 0.4417 | 0.4417 |
| Leishmania major | cell division protein kinase 2,cdc2-related kinase | 0.0556 | 0.6521 | 1 |
| Schistosoma mansoni | serine/threonine protein kinase | 0.0556 | 0.6521 | 0.6521 |
| Plasmodium vivax | protein kinase Crk2 | 0.0556 | 0.6521 | 1 |
| Giardia lamblia | Kinase, CMGC CDK | 0.0556 | 0.6521 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.055 | 0.6438 | 0.6438 |
| Echinococcus granulosus | cyclin dependent kinase 5 | 0.0556 | 0.6521 | 0.6521 |
| Trypanosoma cruzi | cdc2-related kinase 1 | 0.0556 | 0.6521 | 1 |
| Trichomonas vaginalis | CMGC family protein kinase | 0.0556 | 0.6521 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (functional) | > 300 mg kg-1 | Anticonvulsant activity was evaluated by metrazole-induced convulsion test and was determined 30 min after subcutaneous administration | ChEMBL. | 6694169 |
| Activity (functional) | = 300 mg kg-1 | Anticonvulsant activity was evaluated by maximal electroshock induced convulsion test and was determined 30 min after subcutaneous administration | ChEMBL. | 6694169 |
| Activity (ADMET) | > 300 mg kg-1 | Anticonvulsant activity was evaluated by rotorod toxicity test and was determined 30 min after subcutaneous administration | ChEMBL. | 6694169 |
| No. of animals protected (functional) | = 0 | Number of animal protected out of 1 was evaluated by metrazole-induced convulsion test at 30 min after subcutaneous administration of >300 mg/kg | ChEMBL. | 6694169 |
| No. of animals protected (functional) | = 0 | Number of animal protected out of 1 was evaluated by metrazole-induced convulsion test at 30 min after subcutaneous administration of >300 mg/kg | ChEMBL. | 6694169 |
| No. of animals protected (functional) | = 0 | Number of animals protected out of 4 was evaluated by rotorod toxicity test and was determined 30 min t 30 min after subcutaneous administration of >300 mg/kg | ChEMBL. | 6694169 |
| No. of animals protected (functional) | = 1 | Number of animals protected out of 1 was evaluated by maximal electroshock induced convulsion test at 30 min after subcutaneous administration of >300 mg/kg | ChEMBL. | 6694169 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL62177
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.